JPH10276790A - Synthetic method and purification method of anti-tumor substance by degradation of tumor cells and tumor products by enterobacteria and Ray bacteria - Google Patents
Synthetic method and purification method of anti-tumor substance by degradation of tumor cells and tumor products by enterobacteria and Ray bacteriaInfo
- Publication number
- JPH10276790A JPH10276790A JP9124632A JP12463297A JPH10276790A JP H10276790 A JPH10276790 A JP H10276790A JP 9124632 A JP9124632 A JP 9124632A JP 12463297 A JP12463297 A JP 12463297A JP H10276790 A JPH10276790 A JP H10276790A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- substance
- chloroform
- added
- ray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
(57)【要約】 (修正有)
【課題】腸内菌及びレイ菌による腫瘍細胞及び腫瘍産生
物の分解による抗腫瘍物質の合成法及び精製法の提供。
【解決手段】対象とする腫瘍及び腫瘍産生物をレイ菌、
大腸菌等に分解せしめ対象腫瘍に対する抗腫瘍物質(変
性及び増殖抑制物質)を合成する。上記生成物を以下の
通り抽出精製する。
培養液を加熱滅菌しアルコールを添加、ろ過、アルコ
ールを蒸発後再度ろ過して非水溶性物を除く。
アセトンを添加、アセトン凝固物除去。
クロロホルムを原液の2倍量加えクロロホルム凝固物
を除去後、クロロホルム可溶性寒冷凝集物を抽出。
上記に2倍量のエーテルを加えエーテル可溶物を移行
せしめる。
かくして得られた原液をブタノール:氷酢酸:水=
4:1:2系にてペーパークロマト下降法にて展開しR
f=0.16前後ニンヒドリン反応陽性物を得る(57) [Summary] (Corrected) [PROBLEMS] To provide a method for synthesizing and purifying an antitumor substance by decomposing tumor cells and tumor products by enterobacteria and Ray bacteria. A tumor and a tumor product of interest are Ray bacilli,
It is decomposed into Escherichia coli or the like to synthesize an antitumor substance (denaturation and growth inhibitory substance) for the target tumor. The above product is extracted and purified as follows. The culture solution is sterilized by heating, alcohol is added, filtration is performed, and the alcohol is evaporated and then filtered again to remove water-insoluble substances. Acetone was added and acetone coagulated matter was removed. Chloroform was added twice as much as the stock solution to remove chloroform coagulation, and then chloroform-soluble cold aggregates were extracted. To the above is added twice the amount of ether to transfer the ether-soluble matter. The stock solution thus obtained is butanol: glacial acetic acid: water =
Developed by paper chromatography descending method in 4: 1: 2 system and R
Obtain a ninhydrin reaction positive substance around f = 0.16
Description
【発明の詳細な説明】 1. 本発明は対称とする腫瘍及び腫瘍産生物をレイ
菌、大腸菌等に分解せしめ対称腫瘍に対する抗腫瘍物質
(変性及び増殖抑制物質)を合成したことである。この
様に腫瘍及び腫瘍産生物を菌に分解せしめ、抗腫瘍物質
を合成したことは未だ報告されていない。 従来の抗ガ
ン剤は化学合成されたものか、非腫瘍生物からの抽出物
である この手法を用いて癌患者を助けることが可能で
あると考える。DETAILED DESCRIPTION OF THE INVENTION The present invention is to synthesize antitumor substances (degeneration and growth inhibitory substances) against symmetric tumors by decomposing tumors and tumor products to be symmetrical into Ley bacteria, Escherichia coli and the like. It has not yet been reported that tumors and tumor products were decomposed into bacteria to synthesize antitumor substances. Conventional anticancer drugs are chemically synthesized or extracts from non-tumorous organisms. We believe that this approach can be used to help cancer patients.
2. 合成方法. 腫瘍細胞(この実験ではエールリッ
ヒ腫瘍細胞を用いている)及びその培溶液500mlを
加熱滅菌し上記細菌を移植し36.5℃前後で約一週間
培養する。2. Synthesis method. The tumor cells (Ehrlich tumor cells are used in this experiment) and 500 ml of a culture solution thereof are heat-sterilized, transplanted with the above bacteria, and cultured at about 36.5 ° C. for about one week.
温度条件の理由. 30℃で細菌を培養したときと37
℃で培養したとき菌の働きは異なっている。Reason for temperature condition. When the bacteria were cultured at 30 ° C and 37
The function of the bacterium is different when cultured at ℃.
例.レイ菌は30℃ではプロデイギオジンを産生するが
(赤色)37℃では、白色菌コロニーをつくる(プロデ
イギオジンを作らず)又、生体体表温度は36.5℃前
後である。Example. Ray bacteria produce prodegiodin at 30 ° C. (red), but form white colonies at 37 ° C. (not produce prodegiodin), and the surface temperature of the living body is around 36.5 ° C.
生成物の柚出方法 以下抽出精製法を順に従い列挙する。Method for extracting the product The extraction and purification methods are listed below in order.
培養液を加熱滅菌しアルコールを添加(最終濃度
80%)後東洋ろ紙でろ過する。アルコールを蒸発せし
め室温にて再度ろ過して非水溶性物を除く。The culture solution is heat-sterilized, and alcohol is added (final concentration: 80%), followed by filtration through Toyo filter paper. The alcohol is evaporated and filtered again at room temperature to remove water-insoluble materials.
アセトンを添加(アセトン最終濃度80%)後ア
セトン凝固物除去後、アセトンを蒸発除去する。After the addition of acetone (final concentration of acetone: 80%), the solidified acetone is removed, and the acetone is evaporated off.
クロロホルムを原液の2倍量加えよく振盪してク
ロロホルム凝固物を除去後、水層を除去しこのクロロホ
ルム層を10℃以下の所に置き生成せる白濁凝固物をろ
紙にて分別し、このろ紙を水中に入れてクロロホルム可
溶性寒冷凝集物を抽出する。Chloroform was added twice as much as the stock solution, and the mixture was shaken well to remove the chloroform coagulation. The aqueous layer was removed. Extract the chloroform soluble cold aggregates in water.
クロロホルム可溶性寒冷凝集物含有液の2倍量の
エーテルを加えよく振盪してエーテル可溶物を移行せし
め後にエーテルを除去する。Ether is added twice as much as the chloroform-containing solution containing the cold aggregate, and the mixture is shaken well to transfer the ether-soluble matter, and then the ether is removed.
かくして得られた原液をブタノール:氷酢酸:水
=4:1:2系にてペーパークロマト下降法にて展開し
Rf=0.16前後 ニンヒドリン反応陽性物を得る
(原分解材料原液500mlの時は上記物質含有液2m
lを作成して実験を行なう) 尚添付せる写真の様な結
晶構造を示している。今回発見せる物質の性質をまとめ
ると非熱凝固性、アルコール、アセトン、クロロホルム
可溶性、エーテル非可溶性且つクロロホルム溶解中 寒
冷凝集性を有する。The undiluted solution thus obtained is developed by paper chromatography in a butanol: glacial acetic acid: water = 4: 1: 2 system to obtain a ninhydrin reaction positive substance at around Rf = 0.16. 2m of the above substance-containing liquid
The experiment is carried out by creating a l). A crystal structure like a photograph attached is shown. The properties of the substances discovered this time are summarized as non-coagulable, soluble in alcohol, acetone and chloroform, insoluble in ether, and cold aggregating during chloroform dissolution.
以上の抽出法においてクロロホルム可溶物を寒冷凝集さ
せる手法を見いだしたのが最大の特徴である。The most characteristic feature of the above extraction method is that a method of cold-aggregating chloroform-soluble matter has been found.
[使用実例と結果] (実例) エールリッヒ細胞腹腔内移植3日目のマウス
に3日に一度の皮下注射にて0.5mlづつ前記せる抽
出液を投与する。エールリッヒ細胞移植後11.14.
17.日目に腹水を採取し、ギムザ染色にて細胞を観察
した。上記実験手順を以下に図示する。 [Examples of Use and Results] (Examples) A mouse on the third day of Ehrlich cell intraperitoneal transplantation is administered with 0.5 ml of the above extract by subcutaneous injection once every three days. 11.14 after Ehrlich cell transplantation.
17. On the day, ascites was collected and cells were observed by Giemsa staining. The above experimental procedure is illustrated below.
(結果) 細胞の破壊が添付せる写真の様に観察され、
細胞が膨化破裂している核は結合を粗にしている。従来
の抗腫瘍物質は腫瘍細胞の増殖抑制を主としていたが、
この度申請している物質は、腫瘍細胞の破壊を作用の主
としている所が特徴である。尚、腫瘍細胞の生成量は対
称群に対しその1/2以下に抑制される。実験体の各種
他臓器の変性は認められなかった。 (Results) Cell destruction is observed as shown in the attached photo,
The nucleus where the cells are swollen and ruptured loosely binds. Conventional anti-tumor substances mainly suppress the growth of tumor cells,
The substance that has been filed this time is characterized by its main function of destroying tumor cells. Note that the amount of tumor cells generated is suppressed to 1 / or less of the symmetric group. No degeneration of various other organs of the experimental body was observed.
以上のように、目標腫瘍細胞に対してその腫瘍細胞及び
その産生物を細菌に分解せしめて抗腫瘍性物質の生合成
は未だその報告例をみない。化学的性質を用いて資料を
精製する方法はすでに確立されているが、前記抽出液方
法中にのべたごとく、クロロホルム可溶性で且つ寒冷凝
集をきたす性質を利用して目的物質を取得したのがこの
精製方法の一大特徴である。ここに請求された合成手法
と精製法を利用して対腫瘍療法の新しい分野が開かれる
と考える。 As described above, there is no report on biosynthesis of an antitumor substance by decomposing a tumor cell and its product into bacteria with respect to a target tumor cell. Although a method for purifying materials using chemical properties has already been established, the target substance was obtained using the property of being soluble in chloroform and causing cold aggregation, as described in the extract method. This is a major feature of the purification method. We believe that a new field of antitumor therapy will be opened using the synthetic and purification methods claimed here.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI C12R 1:43) ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI C12R 1:43)
Claims (3)
腫瘍細胞及び腫瘍細胞産生物の分解の方法1. A method for decomposing tumor cells and tumor cell products by enterobacteria including Ray and Escherichia coli.
精製法及び抗腫瘍物質について2. A method for purifying the antitumor substance produced in [1] and the antitumor substance
化学的、物理的性質と結晶構造について3. The chemical, physical properties and crystal structure of the antitumor substance produced in [1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09124632A JP3088680B2 (en) | 1997-04-07 | 1997-04-07 | Synthetic method of antitumor substance by intestinal bacteria and ray bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP09124632A JP3088680B2 (en) | 1997-04-07 | 1997-04-07 | Synthetic method of antitumor substance by intestinal bacteria and ray bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10276790A true JPH10276790A (en) | 1998-10-20 |
| JP3088680B2 JP3088680B2 (en) | 2000-09-18 |
Family
ID=14890227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09124632A Expired - Lifetime JP3088680B2 (en) | 1997-04-07 | 1997-04-07 | Synthetic method of antitumor substance by intestinal bacteria and ray bacteria |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3088680B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348166B2 (en) | 2005-05-12 | 2008-03-25 | Motohiro Nakajima | Anti-tumor substances |
-
1997
- 1997-04-07 JP JP09124632A patent/JP3088680B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7348166B2 (en) | 2005-05-12 | 2008-03-25 | Motohiro Nakajima | Anti-tumor substances |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3088680B2 (en) | 2000-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3434766C2 (en) | Pharmaceutical preparation | |
| NL8000291A (en) | PROCESS FOR PREPARING INTERFERON TYPE II, THE THERAPEUTIC USE OF INTERFERON TYPE II AND THE BASIC PHARMACEUTICAL PREPARATIONS. | |
| DE1803987A1 (en) | New, physiologically active peptidolipid and process for its production | |
| DE2441454C3 (en) | Antileukemic proteinaceous fraction and its preparation | |
| EP0031285B1 (en) | Immuno-stimulating preparations based on ribosomal rna of klebsiella pneumoniae and process for the preparation of these rna | |
| Blank | The chemical composition of the cell walls of dermatophytes | |
| CN115572711B (en) | A macrophage-derived exosome and injectable gel | |
| JPH08143462A (en) | Immunostimulants and antitumor agents | |
| JPH10276790A (en) | Synthetic method and purification method of anti-tumor substance by degradation of tumor cells and tumor products by enterobacteria and Ray bacteria | |
| US4629627A (en) | Antiviral substance and the manufacturing method thereof | |
| US4209507A (en) | Novel anti-tumor substance and preparation thereof | |
| DE3784768T2 (en) | USE OF COMPOSITIONS BASED ON CROTOXIN, FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF CARCINOMAS. | |
| JPH0515684B2 (en) | ||
| DE2043971B2 (en) | Antitumor substance from haemolytic streptococci | |
| DE2639410C2 (en) | Polypeptide VI-7501 with anti-tumor activity | |
| JP3117964B2 (en) | Antitumor substance | |
| DE2714443C3 (en) | Manufacture of a parenteral solution for the treatment of cancer and skin diseases that are difficult to cure | |
| JP2002179579A (en) | Method for biologically utilizing apoptosis-inducing polysaccharides | |
| JPH03505200A (en) | Processes for the production of therapeutically active agents, especially for use in wound care or geriatrics, and preparations containing such agents. | |
| Wallace | Effect of delayed addition of irradiated cells to small viable tumor inocula | |
| DE69433472T2 (en) | Recognin VACCINES | |
| JPS60178820A (en) | Preparation of antitumor active substance | |
| RU2175552C1 (en) | Method of preparing anticoagulant from sapropel | |
| SU687120A1 (en) | Method of obtaining antiviral preparation from yeast | |
| SU1081171A1 (en) | Process for recovering desoxyribonucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313532 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100714 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100714 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110714 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120714 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130714 Year of fee payment: 13 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |